泽璟制药-U
(688266)
| 流通市值：275.30亿 | | | 总市值：275.30亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 905,391,322.84 | 810,484,651.18 | 593,440,129.02 | 375,650,273.55 |
| 营业收入 | 905,391,322.84 | 810,484,651.18 | 593,440,129.02 | 375,650,273.55 |
| 二、营业总成本 | 272,317,383.64 | 1,025,913,989.8 | 720,231,851.57 | 475,168,324.66 |
| 营业成本 | 27,037,542.9 | 77,633,816.98 | 56,945,764.64 | 38,820,914.93 |
| 税金及附加 | 2,878,661.72 | 8,413,908.82 | 7,132,102.43 | 3,926,379.78 |
| 销售费用 | 136,266,398.56 | 465,358,770.53 | 332,002,770.56 | 211,258,113.88 |
| 管理费用 | 14,968,287.43 | 74,240,714.69 | 46,276,133.16 | 38,686,242.34 |
| 研发费用 | 92,284,575.29 | 429,907,244.96 | 302,778,713.52 | 196,503,538.35 |
| 财务费用 | -1,118,082.26 | -29,640,466.18 | -24,903,632.74 | -14,026,864.62 |
| 其中:利息费用 | 5,995,998.11 | 24,201,125.24 | 17,226,253.89 | 13,872,494.79 |
| 其中:利息收入 | 13,939,683.39 | 55,124,916.89 | 42,491,882.39 | 28,160,739.61 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 554,506.83 | 841,343.86 | 843,948.35 | - |
| 加:投资收益 | 34,456.54 | 358,908.26 | 202,000.77 | 800,771.56 |
| 资产处置收益 | - | 810.44 | 810.44 | 810.44 |
| 资产减值损失(新) | - | -3,358,105.87 | -3,357,813.66 | -3,358,109.26 |
| 信用减值损失(新) | -1,928,352.35 | -117,813.62 | -1,896,484.03 | -1,738,783.39 |
| 其他收益 | 552,654.61 | 49,690,953.67 | 34,236,631.16 | 27,082,192.48 |
| 四、营业利润 | 632,287,204.83 | -168,013,241.88 | -96,762,629.52 | -76,731,169.28 |
| 减:营业外支出 | 516,605.43 | 641,540.89 | 1,557,004.44 | 683,818.74 |
| 五、利润总额 | 631,770,599.4 | -168,654,782.77 | -98,319,633.96 | -77,414,988.02 |
| 减:所得税费用 | -841,973.1 | -3,527,973.26 | -2,722,813.02 | -1,845,042.52 |
| 六、净利润 | 632,612,572.5 | -165,126,809.51 | -95,596,820.94 | -75,569,945.5 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 632,612,572.5 | -165,126,809.51 | -95,596,820.94 | -75,569,945.5 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 632,612,572.5 | -162,946,167.57 | -93,416,179 | -72,803,538.99 |
| 少数股东损益 | - | -2,180,641.94 | -2,180,641.94 | -2,766,406.51 |
| 扣除非经常损益后的净利润 | 632,221,674.4 | -197,855,212.6 | -120,678,951.07 | -102,641,422.42 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 2.39 | -0.62 | -0.35 | -0.28 |
| (二)稀释每股收益 | 2.39 | -0.62 | -0.35 | -0.28 |
| 八、其他综合收益 | -6,314.96 | 366,110.72 | -598,227.97 | -477,198.95 |
| 归属于母公司股东的其他综合收益 | -6,314.96 | 426,533.3 | -537,805.39 | -416,776.37 |
| 九、综合收益总额 | 632,606,257.54 | -164,760,698.79 | -96,195,048.91 | -76,047,144.45 |
| 归属于母公司股东的综合收益总额 | 632,606,257.54 | -162,519,634.27 | -93,953,984.39 | -73,220,315.36 |
| 归属于少数股东的综合收益总额 | - | -2,241,064.52 | -2,241,064.52 | -2,826,829.09 |
| 公告日期 | 2026-04-29 | 2026-03-28 | 2025-10-31 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |